Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2010 - 03 - 09

Menarini launches ADENURIC® (Febuxostat) in Europe

France, Germany, UK and Ireland are the countries where Menarini will launch, for the first time in Europe, ADENURIC® (febuxostat), the innovative drug for gout.
Gout is the most common form of arthritis in men, and is caused by high levels of uric acid in the body (hyperuricaemia).

On 8 th March, the first launch of ADENURIC® took place in France, country in which Ipsen has retained co-promotion rights together with Menarini.
ADENURIC® (febuxostat), will be launched in Uk on 11 th March, in Germany on 15 th March next, and in Ireland on 29 th March 2010.

Menarini and Ipsen, an innovation-driven international specialty pharmaceutical group, have signed an agreement last October 2009 for the exclusive rights to ADENURIC® in 41 countries, covering the European Union, Eastern Europe, including Russia, Ukraine and Belarus, as well as Switzerland, Iceland, Norway, Armenia and Georgia.

ADENURIC® is a molecule of Japanese origin, developed by Teijin Pharma Ltd.,Tokyo. It is the first drug to be made available as an alternative to allopurinol, and addresses a medical need which has been unmet for many years.
ADENURIC® (febuxostat) has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.